Boothbay Fund Management’s Ovid Therapeutics OVID Stock Holding History

Boothbay Fund Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.06M	Buy	927,913 +772,172	+496%	+$1.38M	0.03%	605
2025 Q4	$254K	Sell	155,741 -331,136	-68%	-$510K	﹤0.01%	1531
2025 Q3	$633K	Buy	+486,877	New	+$422K	0.01%	1039
2022 Q2	–	Sell	-71,489	Closed	-$224K	–	2559
2022 Q1	$224K	Hold	71,489	–	–	0.01%	1820
2021 Q4	$229K	Sell	71,489 -40,555	-36%	-$139K	0.01%	1415
2021 Q3	$376K	Sell	112,044 -29,389	-21%	-$107K	0.01%	1221
2021 Q2	$553K	Buy	141,433 +9,599	+7%	+$37.9K	0.02%	952
2021 Q1	$530K	Buy	+131,834	New	+$438K	0.02%	916
2020 Q2	–	Sell	-58,368	Closed	-$174K	–	1074
2020 Q1	$174K	Sell	58,368 -17,370	-23%	-$58.5K	0.01%	677
2019 Q4	$314K	Sell	75,738 -3,657	-5%	-$11.5K	0.03%	595
2019 Q3	$257K	Buy	+79,395	New	+$180K	0.02%	610

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Boothbay Fund Management's OVID Position: Q1 2026 in Review

Boothbay Fund Management increased its Ovid Therapeutics (OVID) stake by 496% in Q1 2026, buying an estimated $1.38M and bringing the position to 927,913 shares worth $2.06M. The position accounts for 0.03% of the portfolio, ranked #605.

Boothbay Fund Management first reported a position in OVID in Q3 2019 and has held it in 11 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Boothbay Fund Management held 927,913 shares of Ovid Therapeutics worth $2.06M as of Q1 2026.
Boothbay Fund Management bought 772,172 Ovid Therapeutics shares in Q1 2026, an estimated $1.38M.
Ovid Therapeutics made up 0.03% of Boothbay Fund Management's portfolio in Q1 2026, its #605 holding.
Boothbay Fund Management first reported a position in Ovid Therapeutics in Q3 2019 and has held it in 11 quarters since.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.